{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:12:02Z","timestamp":1785348722738,"version":"3.55.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001249","name":"University of Tasmania","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001249","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Studies comparing the effects of Angiotensin II (Ang-II) stimulating and inhibiting antihypertensive medications (AHMs) on dementia risk have reported inconsistent findings. Based on the PRISMA guidelines, this study was performed to pool these findings. We searched PubMed, Scopus, Embase Ovid, PsycINFO, and CINAHL from inception to 22 May 2024 for randomised controlled trials (RCTs) and observational studies that compared the use of Ang-II stimulating (thiazides, Ang-II receptor blockers, and dihydropyridine calcium channel blockers) and inhibiting AHMs (\u03b2-blockers, angiotensin-converting enzyme inhibitors, and non-dihydropyridine calcium channel blockers) and the subsequent risk of developing dementia. Two reviewers independently performed study selection, data extraction, and quality assessment. Random effects meta-analysis models were used to calculate hazard ratios (HRs) or risk ratios (RRs) with their confidence intervals (CIs). All-cause dementia was the primary outcome. Alzheimer\u2019s disease (AD), vascular dementia (VD), and mild cognitive impairment (MCI) were secondary outcomes. We included 18 studies with 1,883,283 participants. Observational studies showed that the use of Ang-II stimulating AHMs reduced the risk of all-cause dementia by 13% (HR\u2009=\u20090.87; 95% CI\u2009=\u20090.82\u20130.93) compared with Ang-II inhibiting AHMs. The risk of AD was reduced by 12% (HR\u2009=\u20090.88; 95% CI\u2009=\u20090.86\u20130.90), VD by 19% (HR\u2009=\u20090.81; 95% CI\u2009=\u20090.72\u20130.91), and MCI by 24% (HR\u2009=\u20090.76; 95% CI\u2009=\u20090.68\u20130.85) in these studies. A meta-analysis of four RCTs revealed a non-significant 8% reduction in dementia risk with Ang-II stimulating AHMs versus control (RR\u2009=\u20090.92; 95% CI\u2009=\u20090.79\u20131.08). Observational evidence suggests that Ang-II stimulating AHMs may offer neuroprotective benefits relative to Ang-II inhibiting AHMs.<\/jats:p>","DOI":"10.1007\/s11357-025-01600-1","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T14:32:56Z","timestamp":1743863576000},"page":"5525-5541","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparative effects of angiotensin II stimulating and inhibiting antihypertensives on dementia risk: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0421-4327","authenticated-orcid":false,"given":"Eyayaw Ashete","family":"Belachew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woldesellassie M.","family":"Bezabhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"issue":"10248","key":"1600_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","volume":"396","author":"G Livingston","year":"2020","unstructured":"Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413\u201346.","journal-title":"Lancet"},{"key":"1600_CR2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3233\/JAD-190474","volume":"71","author":"MJ Lennon","year":"2019","unstructured":"Lennon MJ, Makkar SR, Crawford JD, Sachdev PS. Midlife hypertension and Alzheimer\u2019s disease: a systematic review and meta-analysis. J Alzheimer\u2019s Dis. 2019;71:307\u201316.","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"6","key":"1600_CR3","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","volume":"134","author":"KT Mills","year":"2016","unstructured":"Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441\u201350.","journal-title":"Circulation"},{"issue":"1","key":"1600_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1474-4422(19)30393-X","volume":"19","author":"J Ding","year":"2020","unstructured":"Ding J, Davis-Plourde KL, Sedaghat S, Tully PJ, Wang W, Phillips C, et al. Antihypertensive medications and risk for incident dementia and Alzheimer\u2019s disease: a meta-analysis of individual participant data from prospective cohort studies. Lancet Neurol. 2020;19(1):61\u201370.","journal-title":"Lancet Neurol"},{"issue":"19","key":"1600_CR5","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1001\/jama.2020.4249","volume":"323","author":"D Hughes","year":"2020","unstructured":"Hughes D, Judge C, Murphy R, Loughlin E, Costello M, Whiteley W, et al. Association of blood pressure lowering with incident dementia or cognitive impairment: a systematic review and meta-analysis. JAMA. 2020;323(19):1934\u201344.","journal-title":"JAMA"},{"issue":"10","key":"1600_CR6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1080\/14656566.2017.1333599","volume":"18","author":"I Hernandorena","year":"2017","unstructured":"Hernandorena I, Duron E, Vidal J-S, Hanon O. Treatment options and considerations for hypertensive patients to prevent dementia. Expert Opin Pharmacother. 2017;18(10):989\u20131000.","journal-title":"Expert Opin Pharmacother"},{"key":"1600_CR7","doi-asserted-by":"publisher","first-page":"105515","DOI":"10.1016\/j.phrs.2021.105515","volume":"166","author":"L Scotti","year":"2021","unstructured":"Scotti L, Bassi L, Soranna D, Verde F, Silani V, Torsello A, et al. Association between renin-angiotensin-aldosterone system inhibitors and risk of dementia: a meta-analysis. Pharmacol Res. 2021;166:105515.","journal-title":"Pharmacol Res"},{"issue":"6","key":"1600_CR8","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1212\/WNL.0000000000002946","volume":"87","author":"PJ Tully","year":"2016","unstructured":"Tully PJ, Dartigues J-F, Debette S, Helmer C, Artero S, Tzourio C. Dementia risk with antihypertensive use and blood pressure variability: a cohort study. Neurology. 2016;87(6):601\u20138.","journal-title":"Neurology"},{"issue":"9","key":"1600_CR9","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1097\/HJH.0000000000001829","volume":"36","author":"T van Middelaar","year":"2018","unstructured":"van Middelaar T, van Vught LA, van Gool WA, Simons EM, van den Born B-JH, van Charante EPM, et al. Blood pressure-lowering interventions to prevent dementia: a systematic review and meta-analysis. J Hypertens. 2018;36(9):1780\u20137.","journal-title":"J Hypertens"},{"key":"1600_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.neulet.2016.05.003","volume":"624","author":"S Zhuang","year":"2016","unstructured":"Zhuang S, Wang H-F, Li J, Wang H-Y, Wang X, Xing C-M. Renin-angiotensin system blockade use and risks of cognitive decline and dementia: a meta-analysis. Neurosci Lett. 2016;624:53\u201361.","journal-title":"Neurosci Lett"},{"issue":"3","key":"1600_CR11","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3233\/JAD-171119","volume":"62","author":"PG Kehoe","year":"2018","unstructured":"Kehoe PG. The coming of age of the angiotensin hypothesis in Alzheimer\u2019s disease: progress toward disease prevention and treatment? J Alzheimers Dis. 2018;62(3):1443\u201366.","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"1600_CR12","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1476-5381.2010.01167.x","volume":"163","author":"M Horiuchi","year":"2011","unstructured":"Horiuchi M, Mogi M. Role of angiotensin II receptor subtype activation in cognitive function and ischaemic brain damage. Br J Pharmacol. 2011;163(6):1122\u201330.","journal-title":"Br J Pharmacol"},{"key":"1600_CR13","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s10571-006-9009-0","volume":"26","author":"JM Saavedra","year":"2006","unstructured":"Saavedra JM, Benicky J, Zhou J. Mechanisms of the anti-ischemic effect of angiotensin II AT 1 receptor antagonists in the brain. Cell Mol Neurobiol. 2006;26:1097\u2013109.","journal-title":"Cell Mol Neurobiol"},{"issue":"2","key":"1600_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10571-015-0285-4","volume":"36","author":"E Hamel","year":"2016","unstructured":"Hamel E, Royea J, Ongali B, Tong X-K. Neurovascular and cognitive failure in Alzheimer\u2019s disease: benefits of cardiovascular therapy. Cell Mol Neurobiol. 2016;36(2):219\u201332.","journal-title":"Cell Mol Neurobiol"},{"key":"1600_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.neubiorev.2018.05.005","volume":"92","author":"JK Ho","year":"2018","unstructured":"Ho JK, Nation DA. Cognitive benefits of angiotensin IV and angiotensin-(1\u20137): a systematic review of experimental studies. Neurosci Biobehav Rev. 2018;92:209\u201325.","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"1600_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.2174\/1567205012666141218140953","volume":"12","author":"RJ Baranello","year":"2015","unstructured":"Baranello RJ, Bharani KL, Padmaraju V, Chopra N, Lahiri DK, Greig NH, et al. Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer\u2019s disease. Curr Alzheimer Res. 2015;12(1):32\u201346.","journal-title":"Curr Alzheimer Res"},{"issue":"9","key":"1600_CR17","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1136\/hrt.2006.107706","volume":"93","author":"MJ Brown","year":"2007","unstructured":"Brown MJ. Renin: friend or foe? Heart. 2007;93(9):1026\u201333.","journal-title":"Heart"},{"issue":"1","key":"1600_CR18","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1212\/WNL.0000000000010996","volume":"96","author":"JW van Dalen","year":"2021","unstructured":"van Dalen JW, Marcum ZA, Gray SL, Barthold D, Moll van Charante EP, van Gool WA, et al. Association of angiotensin II\u2013stimulating antihypertensive use and dementia risk: post hoc analysis of the PreDIVA trial. Neurology. 2021;96(1):e67\u201380.","journal-title":"Neurology"},{"issue":"11","key":"1600_CR19","doi-asserted-by":"publisher","first-page":"e0206705","DOI":"10.1371\/journal.pone.0206705","volume":"13","author":"D Barthold","year":"2018","unstructured":"Barthold D, Joyce G, Wharton W, Kehoe P, Zissimopoulos J. The association of multiple anti-hypertensive medication classes with Alzheimer\u2019s disease incidence across sex, race, and ethnicity. PLoS ONE. 2018;13(11):e0206705.","journal-title":"PLoS ONE"},{"issue":"7","key":"1600_CR20","doi-asserted-by":"publisher","first-page":"e2220680","DOI":"10.1001\/jamanetworkopen.2022.20680","volume":"5","author":"JB Cohen","year":"2022","unstructured":"Cohen JB, Marcum ZA, Zhang C, Derington CG, Greene TH, Ghazi L, et al. Risk of mild cognitive impairment or probable dementia in new users of angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors: a secondary analysis of data from the Systolic Blood Pressure Intervention Trial (SPRINT). JAMA ork Open. 2022;5(7):e2220680-e.","journal-title":"JAMA ork Open"},{"issue":"3","key":"1600_CR21","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1212\/WNL.0000000000008732","volume":"94","author":"R Peters","year":"2020","unstructured":"Peters R, Yasar S, Anderson CS, Andrews S, Antikainen R, Arima H, et al. Investigation of antihypertensive class, dementia, and cognitive decline: a meta-analysis. Neurology. 2020;94(3):e267\u201381.","journal-title":"Neurology"},{"issue":"1","key":"1600_CR22","doi-asserted-by":"publisher","first-page":"e2145319","DOI":"10.1001\/jamanetworkopen.2021.45319","volume":"5","author":"ZA Marcum","year":"2022","unstructured":"Marcum ZA, Cohen JB, Zhang C, Derington CG, Greene TH, Ghazi L, et al. Association of antihypertensives that stimulate vs inhibit types 2 and 4 angiotensin II receptors with cognitive impairment. JAMA Netw Open. 2022;5(1):e2145319-e.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"1600_CR23","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/HJH.0000000000003324","volume":"41","author":"JL Schroevers","year":"2023","unstructured":"Schroevers JL, Eggink E, Hoevenaar-Blom MP, Van Dalen JW, Van Middelaar T, Van Gool WA, et al. Antihypertensive medication classes and the risk of dementia over a decade of follow-up. J Hypertens. 2023;41(2):262\u201370.","journal-title":"J Hypertens"},{"key":"1600_CR24","doi-asserted-by":"publisher","first-page":"1136475","DOI":"10.3389\/fcvm.2023.1136475","volume":"10","author":"XL Du","year":"2023","unstructured":"Du XL, Li Z, Schulz PE. Angiotensin-II stimulating vs. inhibiting antihypertensive drugs and the risk of Alzheimer\u2019s disease or related dementia in a large cohort of older patients with colorectal cancer. Front Cardiovasc Med. 2023;10:1136475.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"1600_CR25","doi-asserted-by":"publisher","first-page":"e2249370","DOI":"10.1001\/jamanetworkopen.2022.49370","volume":"6","author":"ZA Marcum","year":"2023","unstructured":"Marcum ZA, Gabriel N, Bress AP, Hernandez I. Association of new use of antihypertensives that stimulate vs inhibit type 2 and 4 angiotensin II receptors with dementia among Medicare beneficiaries. JAMA Netw Open. 2023;6(1):e2249370.","journal-title":"JAMA Netw Open"},{"key":"1600_CR26","doi-asserted-by":"publisher","first-page":"100927","DOI":"10.1016\/j.lanepe.2024.100927","volume":"42","author":"JL Schroevers","year":"2024","unstructured":"Schroevers JL, Hoevenaar-Blom MP, Busschers WB, Hollander M, Van Gool WA, Richard E, et al. Antihypertensive medication classes and risk of incident dementia in primary care patients: a longitudinal cohort study in the Netherlands. Lancet Reg Health Europe. 2024;42:100927.","journal-title":"Lancet Reg Health Europe"},{"key":"1600_CR27","unstructured":"Belachew EA, Peterson G, Bezabhe W.Comparing dementia preventive effects of angiotensin II\u2013stimulating and inhibiting antihypertensives: a systematic review and meta analysis. PROSPERO. 2024 [CRD42024542844]. Available from: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=42024542844"},{"issue":"372","key":"1600_CR28","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. an updated guideline for reporting systematic reviews. BMJ. 2021;29(372):n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1600_CR29","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1600_CR30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3389\/fnagi.2020.00154","volume":"12","author":"W Hu","year":"2020","unstructured":"Hu W, Li Y, Zhao Y, Dong Y, Cui Y, Sun S, et al. Telmisartan and rosuvastatin synergistically ameliorate dementia and cognitive impairment in older hypertensive patients with apolipoprotein E genotype. Front Aging Neurosci. 2020;12:154.","journal-title":"Front Aging Neurosci"},{"issue":"7","key":"1600_CR31","doi-asserted-by":"publisher","first-page":"939-","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology. 1984;34(7):939-.","journal-title":"Neurology"},{"issue":"3","key":"1600_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7(3):263\u20139.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"3","key":"1600_CR33","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/WAD.0000000000000034","volume":"28","author":"P Sachdev","year":"2014","unstructured":"Sachdev P, Kalaria R, O\u2019Brien J, Skoog I, Alladi S, Black SE, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206\u201318.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"5","key":"1600_CR34","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/HRP.0000000000000090","volume":"23","author":"PS Sachdev","year":"2015","unstructured":"Sachdev PS, Mohan A, Taylor L, Jeste DV. DSM-5 and mental disorders in older individuals: an overview. Harv Rev Psychiatry. 2015;23(5):320\u20138.","journal-title":"Harv Rev Psychiatry"},{"issue":"3","key":"1600_CR35","first-page":"Cd010783","volume":"2015","author":"I Arevalo-Rodriguez","year":"2015","unstructured":"Arevalo-Rodriguez I, Smailagic N, Roqu\u00e9 IFM, Ciapponi A, Sanchez-Perez E, Giannakou A, et al. Mini-Mental State Examination (MMSE) for the detection of Alzheimer\u2019s disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2015;2015(3):Cd010783.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1600_CR36","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/BF01109053","volume":"2","author":"RW Elwood","year":"1991","unstructured":"Elwood RW. The Wechsler Memory Scale-Revised: psychometric characteristics and clinical application. Neuropsychol Rev. 1991;2(2):179\u2013201.","journal-title":"Neuropsychol Rev"},{"issue":"4","key":"1600_CR37","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"1600_CR38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1161\/01.STR.27.1.30","volume":"27","author":"T Wetterling","year":"1996","unstructured":"Wetterling T, Kanitz RD, Borgis KJ. Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN). Stroke. 1996;27(1):30\u20136.","journal-title":"Stroke"},{"issue":"5","key":"1600_CR39","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00415-019-09506-7","volume":"268","author":"L Zhuang","year":"2021","unstructured":"Zhuang L, Yang Y, Gao J. Cognitive assessment tools for mild cognitive impairment screening. J Neurol. 2021;268(5):1615\u201322.","journal-title":"J Neurol"},{"issue":"3","key":"1600_CR40","doi-asserted-by":"publisher","first-page":"494","DOI":"10.11124\/JBIES-22-00430","volume":"21","author":"TH Barker","year":"2023","unstructured":"Barker TH, Stone JC, Sears K, Klugar M, Tufanaru C, Leonardi-Bee J, Aromataris E, Munn Z. The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials. JBI Evid Synth. 2023;21(3):494\u2013506.","journal-title":"JBI Evid Synth"},{"key":"1600_CR41","doi-asserted-by":"publisher","unstructured":"Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, Lisy K, Qureshi R, Mattis P, Mu P; Systematic reviews of etiology and risk (2020) Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z, editors. JBI Man Evid Synth. JBI; 2024. Available from: https:\/\/synthesismanual.jbi.global. https:\/\/doi.org\/10.46658\/JBIMES-24-06.","DOI":"10.46658\/JBIMES-24-06"},{"issue":"5","key":"1600_CR42","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/pon.5623","volume":"30","author":"ABC Dijkshoorn","year":"2021","unstructured":"Dijkshoorn ABC, van Stralen HE, Sloots M, Schagen SB, Visser-Meily JMA, Schepers VPM. Prevalence of cognitive impairment and change in patients with breast cancer: a systematic review of longitudinal studies. Psychooncology. 2021;30(5):635\u201348.","journal-title":"Psychooncology"},{"issue":"9","key":"1600_CR43","first-page":"1069","volume":"163","author":"C Tzourio","year":"2003","unstructured":"Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, et al. PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch InternMed. 2003;163(9):1069\u201375.","journal-title":"Arch InternMed"},{"key":"1600_CR44","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.","journal-title":"Trials"},{"key":"1600_CR45","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane. 2023. Available from www.training.cochrane.org\/handbook"},{"issue":"11","key":"1600_CR46","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"key":"1600_CR47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12874-015-0024-z","volume":"15","author":"PT Von Hippel","year":"2015","unstructured":"Von Hippel PT. The heterogeneity statistic I2 can be biased in small meta-analyses. BMC Med Res Methodol. 2015;15:35.","journal-title":"BMC Med Res Methodol."},{"issue":"2","key":"1600_CR48","doi-asserted-by":"publisher","first-page":"197","DOI":"10.5127\/jep.008310","volume":"2","author":"J DeCoster","year":"2011","unstructured":"DeCoster J, Gallucci M, Iselin A-MR. Best practices for using median splits, artificial categorization, and their continuous alternatives. J Exp Psychopathol. 2011;2(2):197\u2013209.","journal-title":"J Exp Psychopathol"},{"issue":"7109","key":"1600_CR49","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"25","key":"1600_CR50","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.1002\/sim.2889","volume":"26","author":"JL Peters","year":"2007","unstructured":"Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med. 2007;26(25):4544\u201362.","journal-title":"Stat Med"},{"issue":"9","key":"1600_CR51","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1038\/s41380-022-01615-6","volume":"27","author":"L Colbourne","year":"2022","unstructured":"Colbourne L, Harrison PJ. Brain-penetrant calcium channel blockers are associated with a reduced incidence of neuropsychiatric disorders. Mol Psychiatry. 2022;27(9):3904\u201312.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"1600_CR52","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/bcp.12511","volume":"79","author":"KL Goh","year":"2015","unstructured":"Goh KL, Bhaskaran K, Minassian C, Evans SJ, Smeeth L, Douglas IJ. Angiotensin receptor blockers and risk of dementia: cohort study in UK Clinical Practice Research Datalink. Br J Clin Pharmacol. 2015;79(2):337\u201350.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"1600_CR53","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1253\/circj.CJ-16-0692","volume":"80","author":"D Hwang","year":"2016","unstructured":"Hwang D, Kim S, Choi H, Oh I-H, Kim BS, Choi HR, et al. Calcium-channel blockers and dementia risk in older adults\u2013National Health Insurance Service\u2013senior cohort (2002\u20132013)\u2013. Circ J. 2016;80(11):2336\u201342.","journal-title":"Circ J"},{"key":"1600_CR54","doi-asserted-by":"publisher","first-page":"b5465","DOI":"10.1136\/bmj.b5465","volume":"340","author":"NC Li","year":"2010","unstructured":"Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010;340:b5465.","journal-title":"BMJ"},{"issue":"2","key":"1600_CR55","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.neurobiolaging.2004.03.009","volume":"26","author":"S Yasar","year":"2005","unstructured":"Yasar S, Corrada M, Brookmeyer R, Kawas C. Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging. Neurobiol Aging. 2005;26(2):157\u201363.","journal-title":"Neurobiol Aging"},{"issue":"10","key":"1600_CR56","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S1474-4422(08)70198-4","volume":"7","author":"HC Diener","year":"2008","unstructured":"Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008;7(10):875\u201384.","journal-title":"Lancet Neurol"},{"issue":"5","key":"1600_CR57","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","volume":"21","author":"H Lithell","year":"2003","unstructured":"Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21(5):875\u201386.","journal-title":"J Hypertens"},{"issue":"10","key":"1600_CR58","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1161\/STROKEAHA.120.033489","volume":"52","author":"WN Whiteley","year":"2021","unstructured":"Whiteley WN, Gupta AK, Godec T, Rostamian S, Whitehouse A, Mackay J, et al. Long-term incidence of stroke and dementia in ASCOT. Stroke. 2021;52(10):3088\u201396.","journal-title":"Stroke"},{"issue":"1","key":"1600_CR59","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3233\/JAD-215657","volume":"87","author":"XL Du","year":"2022","unstructured":"Du XL, Song L, Schulz PE, Xu H, Chan W. Risk of developing Alzheimer\u2019s disease and related dementias in association with cardiovascular disease, stroke, hypertension, and diabetes in a large cohort of women with breast cancer and with up to 26 years of follow-up. J Alzheimer\u2019s Dis. 2022;87(1):415\u201332.","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"7","key":"1600_CR60","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.jamda.2020.12.019","volume":"22","author":"MG den Brok","year":"2021","unstructured":"den Brok MG, van Dalen JW, Abdulrahman H, Larson EB, van Middelaar T, van Gool WA, et al. Antihypertensive medication classes and the risk of dementia: a systematic review and network meta-analysis. J Am Med Dir Assoc. 2021;22(7):1386\u201395 (e15).","journal-title":"J Am Med Dir Assoc"},{"issue":"5","key":"1600_CR61","first-page":"Cd004034","volume":"5","author":"EL Cunningham","year":"2021","unstructured":"Cunningham EL, Todd SA, Passmore P, Bullock R, McGuinness B. Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia. Cochrane Database Syst Rev. 2021;5(5):Cd004034.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1600_CR62","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/jcbfm.2011.133","volume":"32","author":"F Jing","year":"2012","unstructured":"Jing F, Mogi M, Sakata A, Iwanami J, Tsukuda K, Ohshima K, et al. Direct stimulation of angiotensin II type 2 receptor enhances spatial memory. J Cereb Blood Flow Metab. 2012;32(2):248\u201355.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"5","key":"1600_CR63","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00109-008-0316-4","volume":"86","author":"B Maul","year":"2008","unstructured":"Maul B, von Bohlen und Halbach O, Becker A, Sterner-Kock A, Voigt J-P, Siems W-E, et al. Impaired spatial memory and altered dendritic spine morphology in angiotensin II type 2 receptor-deficient mice. J Mol Med. 2008;86(5):563\u201371.","journal-title":"J Mol Med"},{"issue":"4","key":"1600_CR64","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1592\/phco.25.4.531.61022","volume":"25","author":"BJ Epstein","year":"2005","unstructured":"Epstein BJ, Gums JG. Can the renin-angiotensin system protect against stroke? A focus on angiotensin II receptor blockers. Pharmacotherapy. 2005;25(4):531\u20139.","journal-title":"Pharmacotherapy"},{"issue":"12","key":"1600_CR65","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1001\/archneurol.2012.1010","volume":"69","author":"I Hajjar","year":"2012","unstructured":"Hajjar I, Brown L, Mack WJ, Chui H. Impact of angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series. Arch Neurol. 2012;69(12):1632\u20138.","journal-title":"Arch Neurol"},{"issue":"9","key":"1600_CR66","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamaneurol.2015.1001","volume":"72","author":"I Hajjar","year":"2015","unstructured":"Hajjar I, Levey A. Association between angiotensin receptor blockers and longitudinal decline in tau in mild cognitive impairment. JAMA Neurol. 2015;72(9):1069\u201370.","journal-title":"JAMA Neurol"},{"key":"1600_CR67","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.pbb.2015.04.002","volume":"133","author":"R Goel","year":"2015","unstructured":"Goel R, Bhat SA, Rajasekar N, Hanif K, Nath C, Shukla R. Hypertension exacerbates predisposition to neurodegeneration and memory impairment in the presence of a neuroinflammatory stimulus: protection by angiotensin converting enzyme inhibition. Pharmacol Biochem Behav. 2015;133:132\u201345.","journal-title":"Pharmacol Biochem Behav"},{"issue":"8","key":"1600_CR68","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11906-016-0673-2","volume":"18","author":"R Peters","year":"2016","unstructured":"Peters R, Schuchman M, Peters J, Carlson MC, Yasar S. Relationship between antihypertensive medications and cognitive impairment: part II. Review of physiology and animal studies. Curr Hypertens Rep. 2016;18(8):66.","journal-title":"Curr Hypertens Rep"},{"issue":"3","key":"1600_CR69","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3390\/ijms19030876","volume":"19","author":"L Jackson","year":"2018","unstructured":"Jackson L, Eldahshan W, Fagan SC, Ergul A. Within the brain: the renin angiotensin system. Int J Mol Sci. 2018;19(3):876.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1600_CR70","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.bbadis.2016.03.013","volume":"1862","author":"L Mateos","year":"2016","unstructured":"Mateos L, Perez-Alvarez MJ, Wandosell F. Angiotensin II type-2 receptor stimulation induces neuronal VEGF synthesis after cerebral ischemia. Biochim Biophys Acta (BBA) - Mol Basis Dis. 2016;1862(7):1297\u2013308.","journal-title":"Biochim Biophys Acta (BBA) - Mol Basis Dis"},{"issue":"3","key":"1600_CR71","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s13311-014-0286-x","volume":"11","author":"G Umschweif","year":"2014","unstructured":"Umschweif G, Liraz-Zaltsman S, Shabashov D, Alexandrovich A, Trembovler V, Horowitz M, et al. Angiotensin receptor type 2 activation induces neuroprotection and neurogenesis after traumatic brain injury. Neurotherapeutics. 2014;11(3):665\u201378.","journal-title":"Neurotherapeutics"},{"key":"1600_CR72","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fcvm.2020.00005","volume":"7","author":"C Sierra","year":"2020","unstructured":"Sierra C. Hypertension and the risk of dementia. Front Cardiovasc Med. 2020;7:5.","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"1600_CR73","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jalz.2014.10.008","volume":"11","author":"HM Snyder","year":"2015","unstructured":"Snyder HM, Corriveau RA, Craft S, Faber JE, Greenberg SM, Knopman D, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2015;11(6):710\u20137.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"51","key":"1600_CR74","doi-asserted-by":"publisher","first-page":"47863","DOI":"10.1074\/jbc.M104068200","volume":"276","author":"J Hu","year":"2001","unstructured":"Hu J, Igarashi A, Kamata M, Nakagawa H. Angiotensin-converting enzyme degrades Alzheimer amyloid \u03b2-peptide (A\u03b2); retards A\u03b2 aggregation, deposition, fibril formation; and inhibits cytotoxicity*. J Biol Chem. 2001;276(51):47863\u20138.","journal-title":"J Biol Chem"},{"issue":"45","key":"1600_CR75","doi-asserted-by":"publisher","first-page":"37644","DOI":"10.1074\/jbc.M508460200","volume":"280","author":"ML Hemming","year":"2005","unstructured":"Hemming ML, Selkoe DJ. Amyloid \u03b2-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor*. J Biol Chem. 2005;280(45):37644\u201350.","journal-title":"J Biol Chem"},{"issue":"3","key":"1600_CR76","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.vph.2006.05.002","volume":"45","author":"DV Erbe","year":"2006","unstructured":"Erbe DV, Gartrell K, Zhang Y-L, Suri V, Kirincich SJ, Will S, et al. Molecular activation of PPAR\u03b3 by angiotensin II type 1-receptor antagonists. Vascul Pharmacol. 2006;45(3):154\u201362.","journal-title":"Vascul Pharmacol"},{"issue":"4","key":"1600_CR77","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.bbrc.2009.04.047","volume":"383","author":"J Du","year":"2009","unstructured":"Du J, Zhang L, Liu S, Zhang C, Huang X, Li J, et al. PPAR\u03b3 transcriptionally regulates the expression of insulin-degrading enzyme in primary neurons. Biochem Biophys Res Commun. 2009;383(4):485\u201390.","journal-title":"Biochem Biophys Res Commun"},{"key":"1600_CR78","doi-asserted-by":"publisher","first-page":"123456","DOI":"10.3389\/fnagi.2023.1137197","volume":"15","author":"HW Lee","year":"2023","unstructured":"Lee HW, Kim S, Jo Y, Kim Y, Ye BS, Yu YM. Neuroprotective effect of angiotensin II receptor blockers on the risk of incident Alzheimer\u2019s disease: a nationwide population-based cohort study. Front Aging Neurosci. 2023;15:123456.","journal-title":"Front Aging Neurosci."},{"issue":"6","key":"1600_CR79","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1111\/j.1476-5381.2010.00750.x","volume":"160","author":"TK Ma","year":"2010","unstructured":"Ma TK, Kam KK, Yan BP, Lam YY. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol. 2010;160(6):1273\u201392.","journal-title":"Br J Pharmacol"},{"issue":"19","key":"1600_CR80","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127\u2013248.","journal-title":"J Am Coll Cardiol"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-01600-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-025-01600-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-01600-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T12:04:07Z","timestamp":1757160247000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-025-01600-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":80,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["1600"],"URL":"https:\/\/doi.org\/10.1007\/s11357-025-01600-1","relation":{},"ISSN":["2509-2723"],"issn-type":[{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"21 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}